GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Revenue per Share

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Revenue per Share : $0.00 (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Revenue per Share?

TC BioPharm (Holdings)'s revenue per share for the three months ended in Mar. 2024 was $0.00. TC BioPharm (Holdings)'s revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.

During the past 12 months, the average Revenue Per Share Growth Rate of TC BioPharm (Holdings) was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for TC BioPharm (Holdings)'s Revenue per Share or its related term are showing as below:

During the past 5 years, TC BioPharm (Holdings)'s highest 3-Year average Revenue Per Share Growth Rate was -3.40% per year. The lowest was -3.40% per year. And the median was -3.40% per year.

TCBP's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

TC BioPharm (Holdings) Revenue per Share Historical Data

The historical data trend for TC BioPharm (Holdings)'s Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Revenue per Share Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
160.39 95.00 131.60 137.74 -

TC BioPharm (Holdings) Quarterly Data
Dec19 Sep20 Dec20 Jun21 Sep21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TC BioPharm (Holdings)'s Revenue per Share

For the Biotechnology subindustry, TC BioPharm (Holdings)'s PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TC BioPharm (Holdings)'s PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TC BioPharm (Holdings)'s PS Ratio distribution charts can be found below:

* The bar in red indicates where TC BioPharm (Holdings)'s PS Ratio falls into.



TC BioPharm (Holdings) Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

TC BioPharm (Holdings)'s Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=0/0.309
=0.00

TC BioPharm (Holdings)'s Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as

Revenue Per Share (Q: Mar. 2024 )=Revenue (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=0/1.507
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TC BioPharm (Holdings)  (NAS:TCBP) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


TC BioPharm (Holdings) Revenue per Share Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Traded in Other Exchanges
Address
Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.
Executives
Renaissance Capital Partners Ltd 10 percent owner 42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD